Surgical management of recurrent ovarian cancer

Gynecologic Oncology

Volumn 142, Issue 2, 2016, Pages 357-367

  Suh, Dong Hoon ^a   Kim, Hee Seung ^b   Chang, Suk Joon ^c   Bristow, Robert E ^d  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Ajou University School of Medicine   (South Korea)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cytoreductive surgery; Recurrent ovarian cancer; Selection criteria

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX;

CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; FEMALE; HISTOPATHOLOGY; HUMAN; MORBIDITY; OBSERVATIONAL STUDY; OVARY CANCER; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; TIME TO TREATMENT; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; TUMOR RECURRENCE;

FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84975122026     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2016.04.537     Document Type: Review

References (70)

1. [1] Helm, C.W., Current status and future directions of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of ovarian cancer. Surg. Oncol. Clin. N. Am. 21 (2012), 645–663.
2. [2] Naumann, R.W., Coleman, R.L., Management strategies for recurrent platinum-resistant ovarian cancer. Drugs 71 (2011), 1397–1412.
3. [3] Poveda, A.M., Selle, F., Hilpert, F., Reuss, A., Savarese, A., Vergote, I., et al. Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: analysis by chemotherapy cohort of the randomized phase III AURELIA trial. J. Clin. Oncol. 33 (2015), 3836–3838.
4. [4] Berek, J.S., Hacker, N.F., Lagasse, L.D., Nieberg, R.K., Elashoff, R.M., Survival of patients following secondary cytoreductive surgery in ovarian cancer. Obstet. Gynecol. 61 (1983), 189–193.
5. [5] Harter, P., du Bois, A., Hahmann, M., Hasenburg, A., Burges, A., Loibl, S., et al. Surgery in recurrent ovarian cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann. Surg. Oncol. 13 (2006), 1702–1710.
6. [6] Freyer, G., Ray-Coquard, I., Fischer, D., Martin, A.G., Kielhorn, A., Chia, V., et al. Routine clinical practice for patients with recurrent ovarian carcinoma: results from the TROCADERO study. Int. J. Gynecol. Cancer, 2016.
7. [7] Morris, M., Gershenson, D.M., Wharton, J.T., Secondary cytoreductive surgery in epithelial ovarian cancer: nonresponders to first-line therapy. Gynecol. Oncol. 33 (1989), 1–5.
8. [8] Petrillo, M., Pedone Anchora, L., Tortorella, L., Fanfani, F., Gallotta, V., Pacciani, M., et al. Secondary cytoreductive surgery in patients with isolated platinum-resistant recurrent ovarian cancer: a retrospective analysis. Gynecol. Oncol. 134 (2014), 257–261.
9. [9] Musella, A., Marchetti, C., Palaia, I., Perniola, G., Giorgini, M., Lecce, F., et al. Secondary cytoreduction in platinum-resistant recurrent ovarian cancer: a single-institution experience. Ann. Surg. Oncol. 22 (2015), 4211–4216.
10. [10] Kimball, R.E., Schlaerth, J.B., Kute, T.E., Schlaerth, A.C., Santoso, J., Ballon, S.C., et al. Flow cytometric analysis of lymph node metastases in advanced ovarian cancer: clinical and biologic significance. Am. J. Obstet. Gynecol. 176 (1997), 1319–1326 (discussion 26-7).
11. [11] Fukumura, D., Jain, R.K., Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc. Res. 74 (2007), 72–84.
12. [12] Bristow, R.E., Puri, I., Chi, D.S., Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol. Oncol. 112 (2009), 265–274.
13. [13] Zang, R.Y., Li, Z.T., Tang, J., Cheng, X., Cai, S.M., Zhang, Z.Y., et al. Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits?. Cancer 100 (2004), 1152–1161.
14. [14] Tian, W.J., Chi, D.S., Sehouli, J., Trope, C.G., Jiang, R., Ayhan, A., et al. A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection. Ann. Surg. Oncol. 19 (2012), 597–604.
15. [15] Schorge, J.O., Wingo, S.N., Bhore, R., Heffernan, T.P., Lea, J.S., Secondary cytoreductive surgery for recurrent platinum-sensitive ovarian cancer. Int. J. Gynaecol. Obstet. 108 (2010), 123–127.
16. [16] Harter, P., Heitz, F., Mahner, S., Hilpert, F., du Bois, A., Surgical intervention in relapsed ovarian cancer is beneficial: pro. Ann. Oncol. 24:Suppl. 10 (2013), x33–x34.
17. [17] Shih, K.K., Chi, D.S., Maximal cytoreductive effort in epithelial ovarian cancer surgery. J. Gynecol. Oncol. 21 (2010), 75–80.
18. [18] Oksefjell, H., Sandstad, B., Trope, C., The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer. Ann. Oncol. 20 (2009), 286–293.
19. [19] Chi, D.S., McCaughty, K., Diaz, J.P., Huh, J., Schwabenbauer, S., Hummer, A.J., et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 106 (2006), 1933–1939.
20. [20] Segna, R.A., Dottino, P.R., Mandeli, J.P., Konsker, K., Cohen, C.J., Secondary cytoreduction for ovarian cancer following cisplatin therapy. J. Clin. Oncol. 11 (1993), 434–439.
21. [21] Eisenkop, S.M., Friedman, R.L., Wang, H.J., Secondary cytoreductive surgery for recurrent ovarian cancer. A prospective study. Cancer 76 (1995), 1606–1614.
22. [22] Eisenkop, S.M., Friedman, R.L., Spirtos, N.M., The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer 88 (2000), 144–153.
23. [23] Scarabelli, C., Gallo, A., Carbone, A., Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol. Oncol. 83 (2001), 504–512.
24. [24] Tay, E.H., Grant, P.T., Gebski, V., Hacker, N.F., Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Obstet. Gynecol. 99 (2002), 1008–1013.
25. [25] Wang, F., Ye, Y., Xu, X., Zhou, X., Wang, J., Chen, X., CA-125-indicated asymptomatic relapse confers survival benefit to ovarian cancer patients who underwent secondary cytoreduction surgery. J. Ovarian. Res., 6, 2013, 14.
26. [26] Ayhan, A., Gultekin, M., Taskiran, C., Aksan, G., Celik, N.Y., Dursun, P., et al. The role of secondary cytoreduction in the treatment of ovarian cancer: Hacettepe University experience. Am. J. Obstet. Gynecol. 194 (2006), 49–56.
27. [27] Park, J.Y., Eom, J.M., Kim, D.Y., Kim, J.H., Kim, Y.M., Kim, Y.T., et al. Secondary cytoreductivesurgery in the management of platinum-sensitive recurrent epithelial ovarian cancer. J. Surg. Oncol. 101 (2010), 418–424.
28. [28] Goto, T., Takano, M., Watanabe, A., Miyamoto, M., Kato, M., Hirata, J., et al. Potential survival benefit of secondary cytoreductive surgery for recurrent epithelial ovarian, tubal, and peritoneal cancers. Int. J. Gynecol. Cancer 21 (2011), 263–268.
29. [29] Boran, N., Hizli, D., Yilmaz, S., Turan, T., Celik, B., Karabuk, E., et al. Secondary cytoreductive surgery outcomes of selected patients with paclitaxel/platinum sensitive recurrent epithelial ovarian cancer. J. Surg. Oncol. 106 (2012), 369–375.
30. [30] Schorge, J.O., Garrett, L.A., Goodman, A., Cytoreductive surgery for advanced ovarian cancer: quo vadis?. Oncology 25 (2011), 928–934 (Williston Park).
31. [31] Munkarah, A., Levenback, C., Wolf, J.K., Bodurka-Bevers, D., Tortolero-Luna, G., Morris, R.T., et al. Secondary cytoreductive surgery for localized intra-abdominal recurrences in epithelial ovarian cancer. Gynecol. Oncol. 81 (2001), 237–241.
32. [32] Ferrero, A., Ditto, A., Giorda, G., Gadducci, A., Greggi, S., Daniele, A., et al. Secondary cytoreductive surgery for isolated lymph node recurrence of epithelial ovarian cancer: a multicenter study. Eur. J. Surg. Oncol. 40 (2014), 891–898.
33. [33] Petrillo, M., Fagotti, A., Ferrandina, G., Fanfani, F., Costantini, B., Vizzielli, G., et al. Ovarian cancer patients with localized relapse: clinical outcome and prognostic factors. Gynecol. Oncol. 131 (2013), 36–41.
34. [34] Harter, P., Hahmann, M., Lueck, H.J., Poelcher, M., Wimberger, P., Ortmann, O., et al. Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis. Ann. Surg. Oncol. 16 (2009), 1324–1330.
35. [35] Zang, R.Y., Harter, P., Chi, D.S., Sehouli, J., Jiang, R., Trope, C.G., et al. Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort. Br. J. Cancer 105 (2011), 890–896.
36. [36] Al Rawahi, T., Lopes, A.D., Bristow, R.E., Bryant, A., Elattar, A., Chattopadhyay, S., et al. Surgical cytoreduction for recurrent epithelial ovarian cancer. Cochrane Database Syst. Rev., 2, 2013, CD008765.
37. [37] Lee, C.K., Lord, S., Grunewald, T., Gebski, V., Hardy-Bessard, A.C., Sehouli, J., et al. Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: analysis of the CALYPSO trial. Gynecol. Oncol. 136 (2015), 18–24.
38. [38] Pujade-Lauraine, E., Wagner, U., Aavall-Lundqvist, E., Gebski, V., Heywood, M., Vasey, P.A., et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J. Clin. Oncol. 28 (2010), 3323–3329.
39. [39] van de Laar, R., Zusterzeel, P.L., Van Gorp, T., Buist, M.R., van Driel, W.J., Gaarenstroom, K.N., et al. Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer (SOCceR trial): a multicenter randomised controlled study. BMC Cancer, 14, 2014, 22.
40. [40] Tian, W.J., Jiang, R., Cheng, X., Tang, J., Xing, Y., Zang, R.Y., Surgery in recurrent epithelial ovarian cancer: benefits on survival for patients with residual disease of 0.1–1 cm after secondary cytoreduction. J. Surg. Oncol. 101 (2010), 244–250.
41. [41] Sehouli, J., Richter, R., Braicu, E.I., Buhling, K.J., Bahra, M., Neuhaus, P., et al. Role of secondary cytoreductive surgery in ovarian cancer relapse: who will benefit? A systematic analysis of 240 consecutive patients. J. Surg. Oncol. 102 (2010), 656–662.
42. [42] Harter, P., Sehouli, J., Reuss, A., Hasenburg, A., Scambia, G., Cibula, D., et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the multicenter intergroup study DESKTOP II. A project of the AGO Kommission OVAR, AGO study group, NOGGO, AGO-Austria, and MITO. Int. J. Gynecol. Cancer 21 (2011), 289–295.
43. [43] Hoskins, P., Tu, D., James, K., Pater, J., Koski, B., Factors predictive of survival after first relapse or progression in advanced epithelial ovarian carcinoma: a prediction tree analysis-derived model with test and validation groups. Gynecol. Oncol. 70 (1998), 224–230.
44. [44] van de Laar, R., Massuger, L.F., Van Gorp, T., IntHout, J., Zusterzeel, P.L., Kruitwagen, R.F., External validation of two prediction models of complete secondary cytoreductive surgery in patients with recurrent epithelial ovarian cancer. Gynecol. Oncol. 137 (2015), 210–215.
45. [45] Harter, P., Heitz, F., du Bois, A., Surgery for relapsed ovarian cancer: when should it be offered?. Curr Oncol Rep 14 (2012), 539–543.
46. [46] Harter, P., Beutel, B., Alesina, P.F., Lorenz, D., Boergers, A., Heitz, F., et al. Prognostic and predictive value of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) score in surgery for recurrent ovarian cancer. Gynecol. Oncol. 132 (2014), 537–541.
47. [47] Janco, J.M., Kumar, A., Weaver, A.L., McGree, M.E., Cliby, W.A., Performance of AGO score for secondary cytoreduction in a high-volume U.S. center. Gynecol. Oncol. 141 (2016), 140–147.
48. [48] Angioli, R., Capriglione, S., Aloisi, A., Ricciardi, R., Scaletta, G., Lopez, S., et al. A predictive score for secondary cytoreductive surgery in recurrent ovarian cancer (SeC-score): a single-centre, controlled study for preoperative patient selection. Ann. Surg. Oncol. 22 (2015), 4217–4223.
49. [49] Minaguchi, T., Satoh, T., Matsumoto, K., Sakurai, M., Ochi, H., Onuki, M., et al. Proposal for selection criteria of secondary cytoreductive surgery in recurrent epithelial ovarian, tubal, and peritoneal cancers. Int. J. Clin. Oncol., 2015.
50. [50] Leitao, M.M. Jr., Kardos, S., Barakat, R.R., Chi, D.S., Tertiary cytoreduction in patients with recurrent ovarian carcinoma. Gynecol. Oncol. 95 (2004), 181–188.
51. [51] Karam, A.K., Santillan, A., Bristow, R.E., Giuntoli, R. 2nd, Gardner, G.J., Cass, I., et al. Tertiary cytoreductive surgery in recurrent ovarian cancer: selection criteria and survival outcome. Gynecol. Oncol. 104 (2007), 377–380.
52. [52] Gultekin, M., Velipasaoglu, M., Aksan, G., Dursun, P., Dogan, N.U., Yuce, K., et al. A third evaluation of tertiary cytoreduction. J. Surg. Oncol. 98 (2008), 530–534.
53. [53] Shih, K.K., Chi, D.S., Barakat, R.R., Leitao, M.M. Jr., Tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: an updated series. Gynecol. Oncol. 117 (2010), 330–335.
54. [54] Fotopoulou, C., Richter, R., Braicu, I.E., Schmidt, S.C., Neuhaus, P., Lichtenegger, W., et al. Clinical outcome of tertiary surgical cytoreduction in patients with recurrent epithelial ovarian cancer. Ann. Surg. Oncol. 18 (2011), 49–57.
55. [55] Hizli, D., Boran, N., Yilmaz, S., Turan, T., Altinbas, S.K., Celik, B., et al. Best predictors of survival outcome after tertiary cytoreduction in patients with recurrent platinum-sensitive epithelial ovarian cancer. Eur. J. Obstet. Gynecol. Reprod. Biol. 163 (2012), 71–75.
56. [56] Fotopoulou, C., Zang, R., Gultekin, M., Cibula, D., Ayhan, A., Liu, D., et al. Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation. Ann. Surg. Oncol. 20 (2013), 1348–1354.
57. [57] Fotopoulou, C., Savvatis, K., Kosian, P., Braicu, I.E., Papanikolaou, G., Pietzner, K., et al. Quaternary cytoreductive surgery in ovarian cancer: does surgical effort still matter?. Br. J. Cancer 108 (2013), 32–38.
58. [58] Tang, J., Liu, D.L., Shu, S., Tian, W.J., Liu, Y., Zang, R.Y., Outcomes and patterns of secondary relapse in platinum-sensitive ovarian cancer: implications for tertiary cytoreductive surgery. Eur. J. Surg. Oncol. 39 (2013), 786–791.
59. [59] Fanfani, F., Fagotti, A., Ercoli, A., Gallotta, V., Chiantera, V., Restaino, S., et al. Is there a role for tertiary (TCR) and quaternary (QCR) cytoreduction in recurrent ovarian cancer?. Anticancer Res. 35 (2015), 6951–6955.
60. [60] Shih, K.K., Chi, D.S., Barakat, R.R., Leitao, M.M. Jr., Beyond tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Gynecol. Oncol. 116 (2010), 364–369.
61. [61] Plotti, F., Scaletta, G., Aloisi, A., Luvero, D., Capriglione, S., Miranda, A., et al. Quality of life in platinum-sensitive recurrent ovarian cancer: chemotherapy versus surgery plus chemotherapy. Ann. Surg. Oncol. 22 (2015), 2387–2394.
62. [62] Bamias, A., Psaltopoulou, T., Sotiropoulou, M., Haidopoulos, D., Lianos, E., Bournakis, E., et al. Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy. Cancer 116 (2010), 1462–1468.
63. [63] Crane, E.K., Sun, C.C., Ramirez, P.T., Schmeler, K.M., Malpica, A., Gershenson, D.M., The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer. Gynecol. Oncol. 136 (2015), 25–29.
64. [64] Cheng, X., Jiang, R., Li, Z.T., Tang, J., Cai, S.M., Zhang, Z.Y., et al. The role of secondary cytoreductive surgery for recurrent mucinous epithelial ovarian cancer (mEOC). Eur. J. Surg. Oncol. 35 (2009), 1105–1108.
65. [65] Rustin, G.J., van der Burg, M.E., Griffin, C.L., Guthrie, D., Lamont, A., Jayson, G.C., et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet 376 (2010), 1155–1163.
66. [66] Pignata, S., Cannella, L., Leopardo, D., Bruni, G.S., Facchini, G., Pisano, C., Follow-up with CA125 after primary therapy of advanced ovarian cancer: in favor of continuing to prescribe CA125 during follow-up. Ann. Oncol., 22(Suppl. 8), 2011 (viii40-viii4).
67. [67] Tanner, E.J., Chi, D.S., Eisenhauer, E.L., Diaz-Montes, T.P., Santillan, A., Bristow, R.E., Surveillance for the detection of recurrent ovarian cancer: survival impact or lead-time bias?. Gynecol. Oncol. 117 (2010), 336–340.
68. [68] Fleming, N.D., Cass, I., Walsh, C.S., Karlan, B.Y., Li, A.J., CA125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Gynecol. Oncol. 121 (2011), 249–252.
69. [69] Karam, A.K., Karlan, B.Y., Ovarian cancer: the duplicity of CA125 measurement. Nat. Rev. Clin. Oncol. 7 (2010), 335–339.
70. [70] van de Laar, R., Zusterzeel, P.L., Van Gorp, T., Ottevanger, P.B., Massuger, L.F., Kruitwagen, R.F., The role of surgery in the management of patients with platinum-sensitive recurrent ovarian cancer: survey among Dutch gynecologists and medical oncologists. Gynecol. Oncol. 131 (2013), 561–566.